Newsletter
Newsletter Support JNS

Tel Aviv University study suggests new treatments for esophagus disorder

Eosinophilic esophagitis causes difficulty swallowing, chest and abdominal pain and even child growth delays.

View of the Tel Aviv University campus, May 15, 2025. Photo by Yossi Aloni/Flash90.
View of the Tel Aviv University campus, May 15, 2025. Photo by Yossi Aloni/Flash90.

A study conducted by Tel Aviv University’s Gray Faculty of Medical and Health Sciences may pave the way for an improved treatment of eosinophilic esophagitis, a chronic inflammatory condition of the esophagus linked to food allergies, the school said on Monday.

The medical condition, whose prevalence has grown in Israel and across the Western world over the past decade, causes difficulty swallowing, chest and abdominal pain, and, in children, even growth delays.

The findings published in Allergy, the leading research journal in clinical immunology, identified the TSLP protein as a driver of the condition, suggesting that neutralizing it could ease or even prevent symptoms.

Eosinophilic esophagitis results from an abnormal immune response to foods like milk, eggs, wheat, nuts and fish, leading to an accumulation of eosinophils, a type of white blood cell, in the esophagus. The disease is often linked to other conditions like asthma and atopic dermatitis.

Treatments often involve strict elimination diets or, in severe cases, amino acid–based formulas, which can be challenging for patients.

The research was led by TAU Professor Ariel Munitz and doctoral student Anish Dsilva, in collaboration with Dr. Chen Varol of Tel Aviv Sourasky Medical Center (Ichilov Hospital) and Cincinnati Children’s Hospital Medical Center’s Professor Marc Gothenburg.

Building on a previous experimental model of eosinophilic esophagitis developed in Munitz’s Tel Aviv lab, the team focused on epithelial cells, which form the protective outer layer of the esophagus. It found that in the disease, the epithelial cells release high levels of two proteins, IL-33 and TSLP, which can trigger allergic inflammation.

While removing IL-33 showed little effect, eliminating TSLP prevented disease development in mice. Similarly, using antibodies to neutralize the protein significantly reduced eosinophilic esophagitis symptoms.

These results suggest that therapies targeting TSLP, which TAU said were already under development by pharmaceutical companies, could be effective, potentially even for other allergies.

“This study shows that TSLP is a central player in EoE,” Munitz said. “Given that biologic therapies targeting proteins like TSLP are already in the pipeline, we believe they could become an effective treatment option for patients with this increasingly common and debilitating disease.”

Jewish News Syndicate (JNS) is the fastest-growing news agency covering Israel and the Jewish world. We provide news briefs features opinions and analysis to 100 print newspapers and digital publications on a daily basis.
“We don’t have time to waste,” said Minister Amichai Chikli of the threat of radical Islam in Europe,” as the Israeli government partners with right-wing parties with objectionable pasts.
A 14-year-old Israeli boy allegedly carried out paid tasks for suspected Iranian operatives, filming sensitive sites and spraying pro-regime graffiti.
“At a time when Israel and the U.S. stand shoulder to shoulder in the campaign against the Iranian terrorist regime, this decision carries special significance.”

National Security Council urges travelers to stay alert and avoid unsecured holiday events.
Rescue forces were dispatched to several impact sites in the Sharon coastal region.
Two men held over London ambulance arson; Dutch teens accused of plotting synagogue attack amid surge in antisemitic incidents.